PPARG and inflammatory bowel disease: As we add more targets and anti-targets, the number of candidates decreases: we found, among our ∼2.1 million screened molecules, only 374 candidates for combined (simultaneous) CB2R and PPARγ agonism, which may be tested for SSc (Wei et al., 2010), dermatomyositis, cystic fibrosis, and IBD (Decara et al., 2020).